Extended Data Fig. 9: Cell viability in human hESC-derived pneumocyte-like cells.
From: Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing
a–c, MTT assay performed on human hESC-derived pneumocyte-like cells corresponding to the ones used for infectivity assay in Fig. 4c–e. Data represent mean ± s.e.m. for n = 3 (DMSO, ONO-5334 (a), MDL 28170 (b) and apilimod (c)) and n = 2 (remdesivir) biological replicates.
